Meta-analysis · people

Cerebrolysin: small cognitive gain in vascular dementia, weak evidence

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

For vascular dementia, Cerebrolysin's support comes from a small set of biased trials showing modest gains, so its real-world value is still unproven.

Kind
Meta-analysis
Studied in
People
Number studied
597
Published
2019
Journal
Cochrane Database Syst Rev

What they tested

The team asked whether Cerebrolysin improves thinking, overall function and survival in people with vascular dementia, and whether it causes side effects.

How the study was done

A Cochrane systematic review and meta-analysis, which pools results from many studies, of randomized controlled trials with 597 people, mostly with mild to moderate vascular dementia. The trials used different doses and treatment lengths and followed people for 15 days to 3 years.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking cerebrolysin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In pooled data from 420 people, Cerebrolysin improved scores on thinking tests (MMSE or ADAS-cog+) with a standardized mean difference of 0.36 (95% CI 0.13 to 0.58). A standardized mean difference is a way to combine results from different test scales. In pooled data from 379 people, those on Cerebrolysin were more likely to respond on overall function ratings (risk ratio 2.69, 95% CI 1.82 to 3.98), and side effect rates did not differ (risk ratio 0.91, 95% CI 0.29 to 2.85). The one trial that tracked deaths had none, and all of this evidence was rated very low quality.

What it doesn’t show

The trials were few, had a high risk of bias, and differed a lot from each other, and every trial that named a funder was paid for by the drug industry. No trial measured quality of life or caregiver burden, and the authors noted any benefit might be too small to matter in daily care.

The paper

Cui et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019.

The compound

More studies on Cerebrolysin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking cerebrolysin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo